iCAD (NASDAQ:ICAD) had its price target hoisted by Craig Hallum from $9.00 to $15.00 in a report issued on Thursday morning, The Fly reports. They currently have a buy rating on the technology company’s stock.

Several other research firms have also recently weighed in on ICAD. Dougherty & Co initiated coverage on iCAD in a report on Friday, December 20th. They set a buy rating and a $10.00 price target on the stock. JMP Securities initiated coverage on iCAD in a report on Wednesday, February 5th. They set an outperform rating and a $15.00 price target on the stock. Finally, Lake Street Capital initiated coverage on iCAD in a report on Thursday, January 9th. They set a buy rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $13.50.

Shares of NASDAQ:ICAD traded up $0.22 during midday trading on Thursday, hitting $11.98. 525,000 shares of the stock were exchanged, compared to its average volume of 224,138. The stock has a market capitalization of $226.29 million, a price-to-earnings ratio of -15.56 and a beta of 1.09. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.62 and a current ratio of 1.76. The business’s 50-day moving average price is $8.77 and its 200 day moving average price is $7.34. iCAD has a 12 month low of $4.05 and a 12 month high of $12.32.

Several institutional investors have recently bought and sold shares of ICAD. Cadence Capital Management LLC acquired a new position in shares of iCAD in the third quarter worth approximately $73,000. Charles Schwab Investment Management Inc. acquired a new position in shares of iCAD in the fourth quarter worth approximately $80,000. Virtu Financial LLC acquired a new position in shares of iCAD in the third quarter worth approximately $106,000. California Public Employees Retirement System lifted its stake in shares of iCAD by 3.6% in the fourth quarter. California Public Employees Retirement System now owns 34,271 shares of the technology company’s stock worth $266,000 after acquiring an additional 1,200 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of iCAD in the fourth quarter worth approximately $391,000. 25.46% of the stock is currently owned by institutional investors.

About iCAD

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Featured Article: What is Forex?

The Fly

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.